Primary biliary cholangitis: a comprehensive overview

Hepatology International

Volumn 11, Issue 6, 2017, Pages 485-499

  Lleo, Ana ^a,b   Marzorati, Simona ^a   Anaya, Juan Manuel ^c   Gershwin, M Eric ^d  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b HUMANITAS UNIVERSITY   (Italy)

^c UNIVERSIDAD DEL ROSARIO   (Colombia)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antimitochondrial antibodies; Biliary epithelial cells; Epigenetics; Genetics; Obeticholic acid; Primary biliary cholangitis; Prognostic factors; UDCA

Indexed keywords

ALKALINE PHOSPHATASE; BUDESONIDE; FIBRIC ACID DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MITOCHONDRION ANTIBODY; OBETICHOLIC ACID; URSODEOXYCHOLIC ACID; ANTIINFLAMMATORY AGENT; CHENODEOXYCHOLIC ACID; CHOLAGOGUE;

ADAPTIVE IMMUNITY; AUTOIMMUNE DISEASE; CLINICAL FEATURE; DISEASE COURSE; END STAGE LIVER DISEASE; HISTOPATHOLOGY; HUMAN; IMMUNOFLUORESCENCE; INNATE IMMUNITY; LIVER BIOPSY; LIVER TRANSPLANTATION; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT CARE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BIOPSY; CHOLANGITIS; IMMUNOLOGY; LIVER; PATHOLOGY;

ANTI-INFLAMMATORY AGENTS; AUTOIMMUNE DISEASES; BIOPSY; BUDESONIDE; CHENODEOXYCHOLIC ACID; CHOLAGOGUES AND CHOLERETICS; CHOLANGITIS; FIBRIC ACIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER; PROGNOSIS; URSODEOXYCHOLIC ACID;

EID: 85034650779     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-017-9830-1     Document Type: Review

References (109)

1. Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, et al. Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’. Hepatology. 2015;62(5):1620–2. doi:10.1002/hep.28140 (PubMed PMID: 26372460).
2. Sherlock S. Primary billiary cirrhosis (chronic intrahepatic obstructive jaundice). Gastroenterology. 1959;37:574–86 (PubMed PMID: 14445875).
3. Walker JG, Doniach D, Roitt IM, Sherlock S. Serological tests in diagnosis of primary biliary cirrhosis. Lancet. 1965;39:827–31 (PubMed PMID: 14263538).
4. Gershwin ME, Mackay IR, Sturgess A, Coppel RL. Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. J Immunol. 1987;138(10):3525–31 (PubMed PMID: 3571977).
5. Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol. 2012;56(5):1181–8. doi:10.1016/j.jhep.2011.10.025 (PubMed PMID: 22245904).
6. Kim WR, Lindor KD, Locke GR 3rd, Therneau TM, Homburger HA, Batts KP, et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology. 2000;119(6):1631–6 (PubMed PMID: 11113084).
7. Metcalf JV, Bhopal RS, Gray J, Howel D, James OF. Incidence and prevalence of primary biliary cirrhosis in the city of Newcastle upon Tyne, England. Int J Epidemiol. 1997;26(4):830–6 (PubMed PMID: 9279616).
8. Koulentaki M, Mantaka A, Sifaki-Pistolla D, Thalassinos E, Tzanakis N, Kouroumalis E. Geoepidemiology and space-time analysis of primary biliary cirrhosis in Crete, Greece. Liver Int. 2014;34(7):e200–7. doi:10.1111/liv.12479 (PubMed PMID: 24502439).
9. Watson RG, Angus PW, Dewar M, Goss B, Sewell RB, Smallwood RA. Low prevalence of primary biliary cirrhosis in Victoria, Australia. Melbourne Liver Group. Gut. 1995;36(6):927–30 (PubMed PMID: 7615286; PubMed Central PMCID: PMCPMC1382635).
10. Witt-Sullivan H, Heathcote J, Cauch K, Blendis L, Ghent C, Katz A, et al. The demography of primary biliary cirrhosis in Ontario, Canada. Hepatology. 1990;12(1):98–105 (PubMed PMID: 2197212).
11. Chong VH, Telisinghe PU, Jalihal A. Primary biliary cirrhosis in Brunei Darussalam. Hepatobiliary Pancreat Dis Int. 2010;9(6):622–8 (PubMed PMID: 21134832).
12. Lleo A, Jepsen P, Morenghi E, Carbone M, Moroni L, Battezzati PM, et al. Evolving trends in female to male incidence and male mortality of primary biliary cholangitis. Sci Rep. 2016;6:25906. doi:10.1038/srep25906 (PubMed PMID: 27192935; PubMed Central PMCID: PMCPMC4872151).
13. Kisand KE, Metskula K, Kisand KV, Kivik T, Gershwin ME, Uibo R. The follow-up of asymptomatic persons with antibodies to pyruvate dehydrogenase in adult population samples. J Gastroenterol. 2001;36(4):248–54 (PubMed PMID: 11324728).
14. Marzorati S, Invernizzi P, Lleo A. Making sense of autoantibodies in cholestatic liver diseases. Clin Liver Dis. 2016;20(1):33–46. doi:10.1016/j.cld.2015.08.003 (PubMed PMID: 26593289).
15. Invernizzi P, Podda M, Battezzati PM, Crosignani A, Zuin M, Hitchman E, et al. Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. J Hepatol. 2001;34(3):366–72 (PubMed PMID: 11322196).
16. Courvalin JC, Lassoued K, Worman HJ, Blobel G. Identification and characterization of autoantibodies against the nuclear envelope lamin B receptor from patients with primary biliary cirrhosis. J Exp Med. 1990;172(3):961–7 (PubMed PMID: 2167346; PubMed Central PMCID: PMC2188537).
17. Wesierska-Gadek J, Hohenuer H, Hitchman E, Penner E. Autoantibodies against nucleoporin p62 constitute a novel marker of primary biliary cirrhosis. Gastroenterology. 1996;110(3):840–7 (PubMed PMID: 8608894).
18. Inoue K, Hirohara J, Nakano T, Seki T, Sasaki H, Higuchi K, et al. Prediction of prognosis of primary biliary cirrhosis in Japan. Liver. 1995;15(2):70–7 (PubMed PMID: 7791541).
19. Ahrens EH Jr, Payne MA, Kunkel HG, Eisenmenger WJ, Blondheim SH. Primary biliary cirrhosis. Medicine (Baltimore). 1950;29(4):299–364 (PubMed PMID: 14796348).
20. Carbone M, Mells GF, Pells G, Dawwas MF, Newton JL, Heneghan MA, et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastroenterology. 2013;144(3):560e7–569e7. doi:10.1053/j.gastro.2012.12.005 (quiz e13-4; PubMed PMID: 23246637).
21. Longo M, Crosignani A, Battezzati PM, Squarcia Giussani C, Invernizzi P, Zuin M, et al. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut. 2002;51(2):265–9 (PubMed PMID: 12117892).
22. Talwalkar JA, Lindor KD. Primary biliary cirrhosis. Lancet. 2003;362(9377):53–61 (PubMed PMID: 12853201).
23. Findor J, He XS, Sord J, Terg R, Gershwin ME. Primary biliary cirrhosis and hepatocellular carcinoma. Autoimmun Rev. 2002;1(4):220–5 (PubMed PMID: 12848999).
24. Trivedi PJ, Lammers WJ, van Buuren HR, Pares A, Floreani A, Janssen HL, et al. Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. Gut. 2016;65(2):321–9. doi:10.1136/gutjnl-2014-308351 (PubMed PMID: 25567117).
25. Hewagama A. Role of X-chromosome encoded miRNAs in autoimmunity: suppressing the suppressor and female predisposition. Rheumatol Curr Res. 2013;3(1):1000118.
26. Selmi C, Mayo MJ, Bach N, Ishibashi H, Invernizzi P, Gish RG, et al. Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. Gastroenterology. 2004;127(2):485–92 (PubMed PMID: 15300581).
27. Invernizzi P, Ransom M, Raychaudhuri S, Kosoy R, Lleo A, Shigeta R, et al. Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis. Genes Immunity. 2012;13(6):461–8. doi:10.1038/gene.2012.17 (PubMed PMID: 22573116; PubMed Central PMCID: PMC3423484).
28. Liu JZ, Almarri MA, Gaffney DJ, Mells GF, Jostins L, Cordell HJ, et al. Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis. Nat Genet. 2012;44(10):1137–41. doi:10.1038/ng.2395 (PubMed PMID: 22961000; PubMed Central PMCID: PMC3459817).
29. Selmi C, De Santis M, Cavaciocchi F, Gershwin ME. Infectious agents and xenobiotics in the etiology of primary biliary cirrhosis. Dis Markers. 2010;29(6):287–99. doi:10.3233/DMA-2010-0746 (PubMed PMID: 21297248; PubMed Central PMCID: PMC3835616).
30. Selmi C, Cavaciocchi F, Lleo A, Cheroni C, De Francesco R, Lombardi SA, et al. Genome-wide analysis of DNA methylation, copy number variation, and gene expression in monozygotic twins discordant for primary biliary cirrhosis. Front Immunol. 2014;5:128. doi:10.3389/fimmu.2014.00128 (PubMed PMID: 24734033; PubMed Central PMCID: PMC3975093).
31. Lleo A, Liao J, Invernizzi P, Zhao M, Bernuzzi F, Ma L, et al. Immunoglobulin M levels inversely correlate with CD40 ligand promoter methylation in patients with primary biliary cirrhosis. Hepatology. 2012;55(1):153–60. doi:10.1002/hep.24630 (PubMed PMID: 21898485; PubMed Central PMCID: PMC3245335).
32. Invernizzi P, Pasini S, Selmi C, Gershwin ME, Podda M. Female predominance and X chromosome defects in autoimmune diseases. J Autoimmun. 2009;33(1):12–6. doi:10.1016/j.jaut.2009.03.005 (PubMed PMID: 19356902).
33. Invernizzi P, Miozzo M, Battezzati PM, Bianchi I, Grati FR, Simoni G, et al. Frequency of monosomy X in women with primary biliary cirrhosis. Lancet. 2004;363(9408):533–5 (PubMed PMID: 14975617).
34. Prothero KE, Stahl JM, Carrel L. Dosage compensation and gene expression on the mammalian X chromosome: one plus one does not always equal two. Chromosome Res. 2009;17(5):637–48. doi:10.1007/s10577-009-9063-9 (PubMed PMID: 19802704; PubMed Central PMCID: PMC4941101).
35. Miozzo M, Selmi C, Gentilin B, Grati FR, Sirchia S, Oertelt S, et al. Preferential X chromosome loss but random inactivation characterize primary biliary cirrhosis. Hepatology. 2007;46(2):456–62. doi:10.1002/hep.21696 (PubMed PMID: 17659578).
36. Lleo A, Selmi C, Invernizzi P, Podda M, Coppel RL, Mackay IR, et al. Apotopes and the biliary specificity of primary biliary cirrhosis. Hepatology. 2009;49(3):871–9. doi:10.1002/hep.22736 (PubMed PMID: 19185000; PubMed Central PMCID: PMC2665925).
37. Leung PS, Rossaro L, Davis PA, Park O, Tanaka A, Kikuchi K, et al. Antimitochondrial antibodies in acute liver failure: implications for primary biliary cirrhosis. Hepatology. 2007;46(5):1436–42. doi:10.1002/hep.21828 (PubMed PMID: 17657817; PubMed Central PMCID: PMC3731127).
38. Youinou P. B cell conducts the lymphocyte orchestra. J Autoimmun. 2007;28(2–3):143–51. doi:10.1016/j.jaut.2007.02.011 (PubMed PMID: 17363215).
39. Lleo AIP, Mackay IR, Prince H, Zhong R-Q, Gershwin ME. Etiopathogenesis of primary biliary cirrhosis. World J Gastroenterol. 2008;14(21):3328–37. doi:10.3748/wjg.14.3328.
40. Chuanga Y-H, Lian Z-X, Tsuneyamab K, Chiangc B-L, Ansarid AA, Coppele RL, Gershwin ME. Increased killing activity and decreased cytokine production in NK cells in patients with primary biliary cirrhosis. J Autoimmun. 2006;26(4):232–40. doi:10.1016/j.jaut.2006.04.001 (PubMed PMID: 16730427).
41. Mao TK, Lian Z-X, Selmi C, Ichiki Y, Ashwood P, Ansari AA, Coppel RL, Shimoda S, Ishibashi H, Gershwin ME. Altered monocyte responses to defined TLR ligands in patients with primary biliary cirrhosis. Hepatology. 2005;42:802–8.
42. Fava GGS, Francis H, Alpini G. The immunophysiology of biliary epithelium. Semin Liver Dis. 2005;25(3):251–64.
43. Harada K, Kono N, Tsuneyama K, Nakanuma Y. Cell-kinetic study of proliferating bile ductules in various hepatobiliary diseases. Liver. 1998;18(4):277–84.
44. Gershwin ME, Mackay IR. The causes of primary biliary cirrhosis: convenient and inconvenient truths. Hepatology. 2008;47(2):737–45. doi:10.1002/hep.22042 (PubMed PMID: 18098322).
45. Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid ‘mechanisms of action and clinical use in hepatobiliary disorders’. J Hepatol. 2001;35(1):134–46 (PubMed PMID: 11495032).
46. European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51(2):237–67. doi:10.1016/j.jhep.2009.04.009 (PubMed PMID: 19501929).
47. Lammers WJ, van Buuren HR, Hirschfield GM, Janssen HL, Invernizzi P, Mason AL, et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology. 2014;147(6):1338e5–1349e5. doi:10.1053/j.gastro.2014.08.029 (quiz e15; PubMed PMID: 25160979).
48. Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375(7):631–43. doi:10.1056/NEJMoa1509840 (PubMed PMID: 27532829).
49. Oo YH, Neuberger J. Options for treatment of primary biliary cirrhosis. Drugs. 2004;64(20):2261–71 (PubMed PMID: 15456326).
50. Honda A, Ikegami T, Nakamuta M, Miyazaki T, Iwamoto J, Hirayama T, et al. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology. 2013;57(5):1931–41. doi:10.1002/hep.26018 (PubMed PMID: 22911624).
51. Duclos-Vallee JC, Sebagh M. Recurrence of autoimmune disease, primary sclerosing cholangitis, primary biliary cirrhosis, and autoimmune hepatitis after liver transplantation. Liver Transpl. 2009;15(Suppl 2):S25–34. doi:10.1002/lt.21916 (PubMed PMID: 19876939).
52. Carbone M, Ronca V, Bruno S, Invernizzi P, Mells GF. Toward precision medicine in primary biliary cholangitis. Dig Liver Dis. 2016;48(8):843–50. doi:10.1016/j.dld.2016.05.023 (PubMed PMID: 27324985).
53. Tanaka A, Gershwin ME. Finding the cure for primary biliary cholangitis - Still waiting. Liver Int. 2017;37(4):500–2. doi:10.1111/liv.13344 (PubMed PMID: 28371099).
54. Tanaka T, Zhang W, Sun Y, Shuai Z, Chida AS, Kenny TP, et al. Autoreactive monoclonal antibodies from patients with primary biliary cholangitis recognize environmental xenobiotics. Hepatology. 2017;. doi:10.1002/hep.29245 (PubMed PMID: 28470667).
55. Generali E, Ceribelli A, Stazi MA, Selmi C. Lessons learned from twins in autoimmune and chronic inflammatory diseases. J Autoimmun. 2017;. doi:10.1016/j.jaut.2017.04.005 (PubMed PMID: 28431796).
56. Marzorati S, Lleo A, Carbone M, Gershwin ME, Invernizzi P. The epigenetics of PBC: the link between genetic susceptibility and environment. Clin Res Hepatol Gastroenterol. 2016;40(6):650–9. doi:10.1016/j.clinre.2016.05.011 (PubMed PMID: 27341761).
57. Xiang Z, Yang Y, Chang C, Lu Q. The epigenetic mechanism for discordance of autoimmunity in monozygotic twins. J Autoimmun. 2017;. doi:10.1016/j.jaut.2017.04.003 (PubMed PMID: 28412046).
58. He XS, Gershwin ME, Ansari AA. Checkpoint-based immunotherapy for autoimmune diseases—opportunities and challenges. J Autoimmun. 2017;79:1–3. doi:10.1016/j.jaut.2017.02.004 (PubMed PMID: 28256368).
59. Tang R, Wei Y, Li Y, Chen W, Chen H, Wang Q, et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy. Gut. 2017;. doi:10.1136/gutjnl-2016-313332 (PubMed PMID: 28213609).
60. Shuai Z, Wang J, Badamagunta M, Choi J, Yang G, Zhang W, et al. The fingerprint of antimitochondrial antibodies and the etiology of primary biliary cholangitis. Hepatology. 2017;65(5):1670–82. doi:10.1002/hep.29059 (PubMed PMID: 28100006; PubMed Central PMCID: PMCPMC5397331).
61. Doria A, Gershwin ME, Selmi C. From old concerns to new advances and personalized medicine in lupus: the end of the tunnel is approaching. J Autoimmun. 2016;74:1–5. doi:10.1016/j.jaut.2016.08.007 (PubMed PMID: 27592380).
62. Long H, Yin H, Wang L, Gershwin ME, Lu Q. The critical role of epigenetics in systemic lupus erythematosus and autoimmunity. J Autoimmun. 2016;74:118–38. doi:10.1016/j.jaut.2016.06.020 (PubMed PMID: 27396525).
63. Hisamoto S, Shimoda S, Harada K, Iwasaka S, Onohara S, Chong Y, et al. Hydrophobic bile acids suppress expression of AE2 in biliary epithelial cells and induce bile duct inflammation in primary biliary cholangitis. J Autoimmun. 2016;75:150–60. doi:10.1016/j.jaut.2016.08.006 (PubMed PMID: 27592379).
64. Uchida K, Tanaka T, Gershwin ME, Okazaki K. The geoepidemiology and clinical aspects of IgG4-related disease. Semin Liver Dis. 2016;36(3):187–99. doi:10.1055/s-0036-1584323 (PubMed PMID: 27466790).
65. Bae HR, Leung PS, Tsuneyama K, Valencia JC, Hodge DL, Kim S, et al. Chronic expression of interferon-gamma leads to murine autoimmune cholangitis with a female predominance. Hepatology. 2016;64(4):1189–201. doi:10.1002/hep.28641 (PubMed PMID: 27178326; PubMed Central PMCID: PMCPMC5033675).
66. Jang M, Kim H, Kim Y, Choi J, Jeon J, Hwang Y, et al. The crucial role of IL-22 and its receptor in thymus and activation regulated chemokine production and T-cell migration by house dust mite extract. Exp Dermatol. 2016;25(8):598–603. doi:10.1111/exd.12988 (PubMed PMID: 26914146).
67. Choi J, Selmi C, Leung PS, Kenny TP, Roskams T, Gershwin ME. Chemokine and chemokine receptors in autoimmunity: the case of primary biliary cholangitis. Expert Rev Clin Immunol. 2016;12(6):661–72. doi:10.1586/1744666X.2016.1147956 (PubMed PMID: 26821815; PubMed Central PMCID: PMCPMC4935758).
68. Hirschfield GM, Gershwin ME, Strauss R, Mayo MJ, Levy C, Zou B, et al. Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: a proof-of-concept study. Hepatology. 2016;64(1):189–99. doi:10.1002/hep.28359 (PubMed PMID: 26597786).
69. Hsueh YH, Chang YN, Loh CE, Gershwin ME, Chuang YH. AAV-IL-22 modifies liver chemokine activity and ameliorates portal inflammation in murine autoimmune cholangitis. J Autoimmun. 2016;66:89–97. doi:10.1016/j.jaut.2015.10.005 (PubMed PMID: 26537567; PubMed Central PMCID: PMCPMC4718765).
70. Yang JB, Wang YH, Yang W, Lu FT, Ma HD, Zhao ZB, et al. Successful treatment of murine autoimmune cholangitis by parabiosis: implications for hematopoietic therapy. J Autoimmun. 2016;66:108–17. doi:10.1016/j.jaut.2015.09.002 (PubMed PMID: 26432598; PubMed Central PMCID: PMCPMC4829433).
71. Yang F, Wang Q, Wang Z, Miao Q, Xiao X, Tang R, et al. The natural history and prognosis of primary biliary cirrhosis with clinical features of autoimmune hepatitis. Clin Rev Allergy Immunol. 2016;50(1):114–23. doi:10.1007/s12016-015-8516-5 (PubMed PMID: 26411425).
72. Yang GX, Sun Y, Tsuneyama K, Zhang W, Leung PS, He XS, et al. Endogenous interleukin-22 protects against inflammatory bowel disease but not autoimmune cholangitis in dominant negative form of transforming growth factor beta receptor type II mice. Clin Exp Immunol. 2016;185(2):154–64. doi:10.1111/cei.12806 (PubMed PMID: 27148790; PubMed Central PMCID: PMCPMC4955007).
73. Cordell HJ, Han Y, Mells GF, Li Y, Hirschfield GM, Greene CS, et al. International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways. Nat Commun. 2015;6:8019. doi:10.1038/ncomms9019 (PubMed PMID: 26394269; PubMed Central PMCID: PMCPMC4580981).
74. Triger DR, Berg PA, Rodes J. Epidemiology of primary biliary cirrhosis. Liver. 1984;4(3):195–200 (PubMed PMID: 6748874).
75. Lofgren J, Jarnerot G, Danielsson D, Hemdal I. Incidence and prevalence of primary biliary cirrhosis in a defined population in Sweden. Scand J Gastroenterol. 1985;20(5):647–50 (PubMed PMID: 4023628).
76. Myszor M, James OF. The epidemiology of primary biliary cirrhosis in north-east England: an increasingly common disease? Q J Med. 1990;75(276):377–85 (PubMed PMID: 2385742).
77. Remmel T, Remmel H, Uibo R, Salupere V. Primary biliary cirrhosis in Estonia. With special reference to incidence, prevalence, clinical features, and outcome. Scand J Gastroenterol. 1995;30(4):367–71 (PubMed PMID: 7610354).
78. Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol. 1998;33(1):99–103 (PubMed PMID: 9489916).
79. Prince MI, Chetwynd A, Diggle P, Jarner M, Metcalf JV, James OF. The geographical distribution of primary biliary cirrhosis in a well-defined cohort. Hepatology. 2001;34(6):1083–8. doi:10.1053/jhep.2001.29760 (PubMed PMID: 11731995).
80. Sood S, Gow PJ, Christie JM, Angus PW. Epidemiology of primary biliary cirrhosis in Victoria, Australia: high prevalence in migrant populations. Gastroenterology. 2004;127(2):470–5 (PubMed PMID: 15300579).
81. Sakauchi F, Mori M, Zeniya M, Toda G. A cross-sectional study of primary biliary cirrhosis in Japan: utilization of clinical data when patients applied to receive public financial aid. J Epidemiol. 2005;15(1):24–8 (PubMed PMID: 15678923).
82. Myers RP, Shaheen AA, Fong A, Burak KW, Wan A, Swain MG, et al. Epidemiology and natural history of primary biliary cirrhosis in a Canadian health region: a population-based study. Hepatology. 2009;50(6):1884–92. doi:10.1002/hep.23210 (PubMed PMID: 19821525).
83. Liu H, Liu Y, Wang L, Xu D, Lin B, Zhong R, et al. Prevalence of primary biliary cirrhosis in adults referring hospital for annual health check-up in Southern China. BMC Gastroenterol. 2010;10:100. doi:10.1186/1471-230X-10-100 (PubMed PMID: 20815889; PubMed Central PMCID: PMCPMC2944334).
84. Cheung KS, Seto WK, Fung J, Lai CL, Yuen MF. Epidemiology and natural history of primary biliary cholangitis in the Chinese: a territory-based study in Hong Kong between 2000 and 2015. Clin Transl Gastroenterol. 2017;8(8):e116. doi:10.1038/ctg.2017.43 (PubMed PMID: 28858291).
85. Tsianos EV, Hoofnagle JH, Fox PC, Alspaugh M, Jones EA, Schafer DF, et al. Sjögren’s syndrome in patients with primary biliary cirrhosis. Hepatology. 1990;11(5):730–4 (PubMed PMID: 2347546).
86. Pares A, Rimola A, Bruguera M, Mas E, Rodes J. Renal tubular acidosis in primary biliary cirrhosis. Gastroenterology. 1981;80(4):681–6 (PubMed PMID: 7202940).
87. Costa C, Sambataro A, Baldi S, Modena V, Todros L, Libertucci D, et al. Primary biliary cirrhosis: lung involvement. Liver. 1995;15(4):196–201 (PubMed PMID: 8544642).
88. Marasini B, Gagetta M, Rossi V, Ferrari P. Rheumatic disorders and primary biliary cirrhosis: an appraisal of 170 Italian patients. Ann Rheum Dis. 2001;60(11):1046–9 (PubMed PMID: 11602476).
89. Elta GH, Sepersky RA, Goldberg MJ, Connors CM, Miller KB, Kaplan MM. Increased incidence of hypothyroidism in primary biliary cirrhosis. Dig Dis Sci. 1983;28(11):971–5 (PubMed PMID: 6628157).
90. Kingham JG, Parker DR. The association between primary biliary cirrhosis and coeliac disease: a study of relative prevalences. Gut. 1998;42(1):120–2 (PubMed PMID: 9518232).
91. Gulamhusein AF, Juran BD, Lazaridis KN. Genome-wide association studies in primary biliary cirrhosis. Semin Liver Dis. 2015;35(4):392–401. doi:10.1055/s-0035-1567831 (PubMed PMID: 26676814; PubMed Central PMCID: PMCPMC4683605).
92. Hirschfield GM, Liu X, Xu C, Lu Y, Xie G, Gu X, et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med. 2009;360(24):2544–55. doi:10.1056/NEJMoa0810440 (PubMed PMID: 19458352; PubMed Central PMCID: PMC2857316).
93. Liu X, Invernizzi P, Lu Y, Kosoy R, Bianchi I, Podda M, et al. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet. 2010;42(8):658–60. doi:10.1038/ng.627 (PubMed PMID: 20639880; PubMed Central PMCID: PMC3150510).
94. Mells GF, Floyd JA, Morley KI, Cordell HJ, Franklin CS, Shin SY, et al. Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nat Genet. 2011;43(4):329–32. doi:10.1038/ng.789 (PubMed PMID: 21399635; PubMed Central PMCID: PMCPMC3071550).
95. Nakamura M, Nishida N, Kawashima M, Aiba Y, Tanaka A, Yasunami M, et al. Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population. Am J Hum Genet. 2012;91(4):721–8. doi:10.1016/j.ajhg.2012.08.010 (PubMed PMID: 23000144; PubMed Central PMCID: PMC3484650).
96. Juran BD, Hirschfield GM, Invernizzi P, Atkinson EJ, Li Y, Xie G, et al. Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. Hum Mol Genet. 2012;21(23):5209–21. doi:10.1093/hmg/dds359 (PubMed PMID: 22936693; PubMed Central PMCID: PMC3490520).
97. Li Z, White P, Tuteja G, Rubins N, Sackett S, Kaestner KH. Foxa1 and Foxa2 regulate bile duct development in mice. J Clin Investig. 2009;119(6):1537–45. doi:10.1172/JCI38201 (PubMed PMID: 19436110; PubMed Central PMCID: PMC2689124).
98. Fu S, Fei Q, Jiang H, Chuai S, Shi S, Xiong W, et al. Involvement of histone acetylation of Sox17 and Foxa2 promoters during mouse definitive endoderm differentiation revealed by microRNA profiling. PLoS One. 2011;6(11):e27965. doi:10.1371/journal.pone.0027965 (PubMed PMID: 22132182; PubMed Central PMCID: PMC3223193).
99. McDaniel K, Meng F, Wu N, Sato K, Venter J, Bernuzzi F, et al. Forkhead box A2 regulated biliary heterogeneity and senescence during cholestatic liver injury. Hepatology. 2016;. doi:10.1002/hep.28831 (PubMed PMID: 27639079).
100. Sawalha AH. Epigenetics and T-cell immunity. Autoimmunity. 2008;41(4):245–52. doi:10.1080/08916930802024145 (PubMed PMID: 18432405).
101. Lal G, Zhang N, van der Touw W, Ding Y, Ju W, Bottinger EP, et al. Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J Immunol. 2009;182(1):259–73 (PubMed PMID: 19109157; PubMed Central PMCID: PMC3731994).
102. Kont V, Murumagi A, Tykocinski LO, Kinkel SA, Webster KE, Kisand K, et al. DNA methylation signatures of the AIRE promoter in thymic epithelial cells, thymomas and normal tissues. Mol Immunol. 2011;49(3):518–26. doi:10.1016/j.molimm.2011.09.022 (PubMed PMID: 22036612).
103. Wu H, Zhao M, Chang C, Lu Q. The real culprit in systemic lupus erythematosus: abnormal epigenetic regulation. Int J Mol Sci. 2015;16(5):11013–33. doi:10.3390/ijms160511013 (PubMed PMID: 25988383; PubMed Central PMCID: PMC4463688).
104. Mitchell MM, Lleo A, Zammataro L, Mayo MJ, Invernizzi P, Bach N, et al. Epigenetic investigation of variably X chromosome inactivated genes in monozygotic female twins discordant for primary biliary cirrhosis. Epigenetics. 2011;6(1):95–102. doi:10.4161/epi.6.1.13405 (PubMed PMID: 20864813; PubMed Central PMCID: PMC3029486).
105. Lee JT. Epigenetic regulation by long noncoding RNAs. Science. 2012;338(6113):1435–9. doi:10.1126/science.1231776 (PubMed PMID: 23239728).
106. Ricano-Ponce I, Wijmenga C. Mapping of immune-mediated disease genes. Annu Rev Genomics Hum Genet. 2013;14:325–53. doi:10.1146/annurev-genom-091212-153450 (PubMed PMID: 23834318).
107. Ninomiya M, Kondo Y, Funayama R, Nagashima T, Kogure T, Kakazu E, et al. Distinct microRNAs expression profile in primary biliary cirrhosis and evaluation of miR 505-3p and miR197-3p as novel biomarkers. PLoS One. 2013;8(6):e66086. doi:10.1371/journal.pone.0066086 (PubMed PMID: 23776611; PubMed Central PMCID: PMC3680413).
108. Sander S, Bullinger L, Klapproth K, Fiedler K, Kestler HA, Barth TF, et al. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood. 2008;112(10):4202–12. doi:10.1182/blood-2008-03-147645 (PubMed PMID: 18713946).
109. Padgett KA, Lan RY, Leung PC, Lleo A, Dawson K, Pfeiff J, et al. Primary biliary cirrhosis is associated with altered hepatic microRNA expression. J Autoimmun. 2009;32(3–4):246–53. doi:10.1016/j.jaut.2009.02.022 (PubMed PMID: 19345069; PubMed Central PMCID: PMC2698796).